Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 21, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,000,000 Ordinary Shares of 25 pence each.
- Purchase Date: November 21, 2012.
- Price Range: Highest price paid was 1,339.0 pence per share; lowest price paid was 1,324.5 pence per share.
- Treasury Holdings: 530,140,427 shares held in Treasury (9.74% of total issued share capital).
- Voting Rights Impact: Including unsettled purchases, Treasury shares represent 10.79% of total voting rights.
- Shares in Issue: 4,914,842,606 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 1,000,000 newly purchased shares. This action increases the proportion of voting rights held in Treasury relative to the total issued capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (4,914,842,606) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current Treasury share count (530,140,427) and its impact on voting rights (10.79%).
- Note that the purchased shares are cancelled, permanently reducing the share count.
- Check subsequent filings for further repurchase activity under the May 2012 shareholder authority.